Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1

(1) Background: Short QT syndrome (SQTS) may result in sudden cardiac death. So far, no drugs, except quinidine, have been demonstrated to be effective in some patients with SQTS type 1 (SQTS1). This study was designed to examine the potential effectiveness of vernakalant for treating SQTS1 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qiang, Huang, Xuemei, Meng, Zenghui, Li, Yingrui, Zhong, Rujia, Li, Xin, Cyganek, Lukas, El-Battrawy, Ibrahim, Akin, Ibrahim, Zhou, Xiaobo, Lan, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032933/
https://www.ncbi.nlm.nih.gov/pubmed/35448088
http://dx.doi.org/10.3390/jcdd9040112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032933/
https://www.ncbi.nlm.nih.gov/pubmed/35448088
http://dx.doi.org/10.3390/jcdd9040112

Ejemplares similares